Atossa Therapeutics (Atossa Therapeutics) Total Current Assets : $92.22 Mil (As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is Atossa Therapeutics Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Atossa Therapeutics's total current assets for the quarter that ended in Dec. 2023 was $92.22 Mil.

Atossa Therapeutics Total Current Assets Historical Data

The historical data trend for Atossa Therapeutics's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Atossa Therapeutics Total Current Assets Chart

Atossa Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

14.32

42.77

141.24

118.20

92.22

Atossa Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															118.20	110.87	106.00	97.65	92.22

Atossa Therapeutics Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Atossa Therapeutics's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	88.46	+	0	+	0	+	3.759
	=	92.22

Atossa Therapeutics's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	88.46	+	0	+	0	+	3.759
	=	92.22

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Atossa Therapeutics (NAS:ATOS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Atossa Therapeutics's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	88.46	-	5.236	+	0.75 * 0	+	0.5 * 0
=	83.22

Atossa Therapeutics Total Current Assets Related Terms

Thank you for viewing the detailed overview of Atossa Therapeutics's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Atossa Therapeutics (Atossa Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Atossa Therapeutics Inc (NAS:ATOS) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

ATOS:Mexico YAG2:Germany

Address

107 Spring Street, Seattle, WA, USA, 98104

Website

https://www.atossatherapeutics.com

Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company developing proprietary innovative medicines in areas of significant unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.

Executives

Gregory L Weaver	director	185 BERRY STREET, SUITE 6504, SAN FRANCISCO CA 94107
Heather Rees	officer: SVP, Finance and Accounting	C/O ATOSSA THERAPEUTICS, INC., 107 SPRING STREET, SEATTLE WA 98104
Kyle Guse	officer: CFO & General Counsel	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98102
H. Lawrence Remmel	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
Shu-chih Chen	director, 10 percent owner, officer: Chief Scientific Officer	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112
Steven C Quay	director, 10 percent owner, officer: CEO	22026 20TH AVENUE S E, SUITE 102, BOTHELL WA 98021
Scott Youmans	officer: Chief Operating Officer	ATOSSA GENETICS INC., 2345 EASTLAKE AVE. E, SUITE 201, SEATTLE WA 98102
John E Sawyer	officer: See Remarks	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. E SUITE 510, SEATTLE WA 98021
Christopher S. Destro	officer: SVP, Sales and Marketing	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Peter J. Carbonaro	officer: Sr. Vice President, Operations	C/O ATOSSA GENETICS INC., 1616 EASTLAKE AVE. EAST, SUITE 510, SEATTLE WA 98102
Ben R Chen	officer: Sr. VP of Glob. Reg. Affairs	1616 EASTLAKE AVENUE EAST, SUITE 510, SEATTLE WA 98102
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Alexander D Cross	director	C/O LIGAND PHARMACEUTICALS INC.,, 10275 SCIENCE CENTER DR., SAN DIEGO CA 92121
Stephen J Galli	director	C/O ATOSSA GENETICS, INC., 4105 MADISON STREET, SUITE 320, SEATTLE WA 98112
John Barnhart	director	C/O ATOSSA GENETICS, INC, 4105 E MADISON STREET, SUITE 320, SEATTLE WA 98112